688117 圣诺生物
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)2.4738.2438.00110.01914.741
总资产报酬率 ROA (%)1.5695.8046.2477.90610.792
投入资产回报率 ROIC (%)1.7726.6847.2419.52714.461

边际利润分析
销售毛利率 (%)59.58463.76165.47071.97379.207
营业利润率 (%)11.96718.64318.40719.61318.425
息税前利润/营业总收入 (%)13.46819.54717.89617.75817.844
净利润/营业总收入 (%)10.91716.16616.29615.84715.840

收益指标分析
经营活动净收益/利润总额(%)96.44096.783101.84498.75196.433
价值变动净收益/利润总额(%)2.996-1.7743.4072.0780.000
营业外收支净额/利润总额(%)-2.177-1.223-0.659-7.551-1.317

偿债能力分析
流动比率 (X)1.4852.5252.9604.0132.318
速动比率 (X)0.9351.7202.3583.3891.697
资产负债率 (%)39.64833.10925.38517.92626.208
带息债务/全部投入资本 (%)31.93623.45211.9664.6191.177
股东权益/带息债务 (%)212.059324.497728.4732,041.4798,202.879
股东权益/负债合计 (%)152.203201.990293.929457.857281.560
利息保障倍数 (X)7.66917.315-45.787-37.140-52.257

营运能力分析
应收账款周转天数 (天)82.85386.15192.32592.76885.100
存货周转天数 (天)478.315376.514311.938317.967403.420